^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Rectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Lumakras (sotorasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/21/2023
    Excerpt:
    Rectal Cancer: SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE…Sotorasib + cetuximab (KRAS G12C mutation positive)…